Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Everolimus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    314 result(s) found for: Everolimus. Displaying page 8 of 16.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2013-004153-24 Sponsor Protocol Number: CRAD001JIT36T Start Date*: 2014-05-25
    Sponsor Name:Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche
    Full Title: MAINtenance Afinitor (MAIN-A): A randomized trial comparing maintenance aromatase inhibitors (AIs) + everolimus (Afinitor) vs. AIs in patients withHR+ metastatic breast cancer with disease control ...
    Medical condition: HR+ / HER2 negative metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008698-69 Sponsor Protocol Number: CRAD001Y2301 Start Date*: 2009-07-28
    Sponsor Name:NOVARTIS FARMA
    Full Title: A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metasta...
    Medical condition: estrogen receptor positive locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) CZ (Completed) NL (Completed) FR (Completed) BE (Completed) GB (Completed) DE (Completed) SE (Completed) ES (Completed) HU (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001714-41 Sponsor Protocol Number: CRAD001A2426 Start Date*: 2006-05-24
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Estudio multicéntrico, abierto, randomizado, de doce meses de duración, sobre la seguridad, tolerabilidad y eficacia de Certican®, administrado junto a un antagonista del receptor IL-2, corticoes...
    Medical condition: Transplante renal de novo de novo kidney transplantation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) HU (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2009-013074-41 Sponsor Protocol Number: CRAD001ANO02 Start Date*: 2009-11-10
    Sponsor Name:Novartis Norge AS
    Full Title: A controlled randomized open-label multicentre study evaluating if early initiation of everolimus (Certican®)and early elimination of cyclosporine (Sandimmun Neoral®) in de novo heart transplant re...
    Medical condition: Heart transplantation
    Disease: Version SOC Term Classification Code Term Level
    16.1 10042613 - Surgical and medical procedures 10019314 Heart transplant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2010-018791-24 Sponsor Protocol Number: KM003EPC Start Date*: 2011-07-04
    Sponsor Name:Kliniken der Stadt Koeln gGmbH, Klinikum Merheim
    Full Title: Single-center, single-armed, open-label, prospective study assessing efficacy and safety of a conversion of stable kidney allograft recipients to an Everolimus-based regimen to prevent the developm...
    Medical condition: This study is designed to assess whether a conversion from a CNI-based therapy to a CNI-free therapy with Certican® in stable renal transplant patients is able to prevent the development of Chronic...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002675-41 Sponsor Protocol Number: CRAD001C2455 Start Date*: 2007-05-22
    Sponsor Name:Universitaetsklinikum Schleswig-Holstein
    Full Title: A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple Myeloma
    Medical condition: Multiple Myeloma (Salmon-Durie stage II or III, Relapsed or refractory disease after failure of two or more treatment regimens)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004325-91 Sponsor Protocol Number: CRAD001HIT34 Start Date*: 2014-01-25
    Sponsor Name:NOVARTIS FARMA S.p.A
    Full Title: Multicenter, prospective, open-label, controlled, randomized, parallel groups study to evaluate the renal function of adult liver transplant recipients treated with two everolimus-based immunosuppr...
    Medical condition: liver transplant
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10024716 Liver transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003413-32 Sponsor Protocol Number: CRAD001A2310 Start Date*: 2006-01-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month, multicenter, randomized, open-label non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled Certican with reduced Neoral versus 3.0g MMF with st...
    Medical condition: de novo heart transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) IT (Completed) DK (Prematurely Ended) BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002105-22 Sponsor Protocol Number: EVL-VHC-HVH.12 Start Date*: 2012-08-17
    Sponsor Name:Dra Itxarone Bilbao. Servicio de cirugía hepatobiliopancreatica y trasplantes. HUVH
    Full Title: Personal monitoring of liver transplant patients infected with Hepatitis C Virus. Pilot study to compare the evolution of Hepatitis C by receiving immunosuppression with tacrolimus in combination w...
    Medical condition: Recurrence of hepatitis C post-liver transplantation in patients with hepatitic C.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10070678 Hepatitis C recurrent LLT
    14.1 10042613 - Surgical and medical procedures 10024716 Liver transplantation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-017311-15 Sponsor Protocol Number: CRAD001H2304E1 Start Date*: 2010-03-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Extension study to the multicenter, open-label, randomized, controlled study CRAD001H2304 to evaluate the long-term efficacy and safety of concentration-controlled everolimus in liver transplant re...
    Medical condition: prophylaxis of liver allograft rejection in liver transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066543 Acute allograft rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) NL (Completed) ES (Completed) IT (Completed) DE (Completed) HU (Completed) SE (Completed) GB (Completed) IE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-024231-16 Sponsor Protocol Number: CCHI621AFR05 Start Date*: 2011-06-21
    Sponsor Name:Novartis Pharma S.A.S
    Full Title: Evaluation de la pharmacodynamie, de l’efficacité et de la tolérance de 2 doses de Simulect® (40 ou 80 mg) en association ou non à un inhibiteur de la calcineurine.
    Medical condition: Renal transplantation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-010541-31 Sponsor Protocol Number: MTOR-METAB Start Date*: 2010-10-20
    Sponsor Name:Servicio Nefrología Hospital Universitario de Bellvitge
    Full Title: Efecto de la inhibición de la diana de rapamicina (mTor) sobre el metabolismo y rendimiento en el ejercicio físico
    Medical condition: Pacientes trasplantados renales a los que por indicación clínica se les va a realizar un cambio de un fármaco anti-calcineurínico (Ciclosporina o Tacrolimus) a un inhidor de la diana de rapamicina ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10038533 Renal transplant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005844-26 Sponsor Protocol Number: Cistcert Start Date*: 2008-06-16
    Sponsor Name:Antwerp University Hospital
    Full Title: Multicentre, prospective, randomized, open-label, controlled study in de novo kidney transplant recipients to evaluate the impact of cyclosporine or steroid withdrawal at 3 months on graft function...
    Medical condition: Preservation of renal function after kidney transplantation in a 5-year, multicentre, prospective, randomized, open-label, controlled study Patients will be randomized within 24 hours prior to tra...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004224-37 Sponsor Protocol Number: EREMIT Start Date*: Information not available in EudraCT
    Sponsor Name:Universität Leipzig
    Full Title: Everolimus in der Therapie von Patienten mit pulmonaler Hypertonie
    Medical condition: - steady or progressive pulmonary hypertension accompanied by at least two of the following parameters associated with a poor prognosis: - Cardiac index ≤ 2,1 l/min/m2 - 6 MWD ≤ 380 m - systolic RR...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037400 Pulmonary hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003035-78 Sponsor Protocol Number: 72/2006/U/Sper Start Date*: 2006-07-11
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: SICUREZZA ED EFFICACIA DI CICLOSPORINA A BASSE DOSI IN ASSOCIAZIONE AD EVEROLIMUS NEL PROTEGGERE LA FUNZIONE RENALE NEI PAZIENTI CON TRAPIANTO DI CUORE
    Medical condition: Heart transplant
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019314 Heart transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001929-32 Sponsor Protocol Number: 2014/2126 Start Date*: 2014-08-25
    Sponsor Name:Gustave Roussy
    Full Title: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
    Medical condition: Diffuse Intrinsic Pontine Glioma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Prematurely Ended) ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2012-005481-35 Sponsor Protocol Number: 2012-005481-35 Start Date*: 2013-09-02
    Sponsor Name:Uppsala University Hospital
    Full Title: A controlled, randomized, assessor blinded, open-label study to investigate whether initiation of everolimus will reduce the incidence of developing a new Squamous Cell Carcinoma (SCC) and other ma...
    Medical condition: Squamous cell carcinoma (SCC) and other malignancies in renal transplanted recipients
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021086-73 Sponsor Protocol Number: Uni-Koeln-1443 Start Date*: 2012-05-11
    Sponsor Name:University of Cologne
    Full Title: HD-R3i - A prospective, randomized, placebo-controlled, international, multicenter phase I/II trial of RAD001 (everolimus) in combination with DHAP as induction therapy in patients with relapsed or...
    Medical condition: relapsed or refractory Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020451-32 Sponsor Protocol Number: AMCmedonc010 Start Date*: 2010-12-10
    Sponsor Name:Academic Medical Center Amsterdam
    Full Title: Pilot study of everolimus in the treatment of advanced malignancies in patients with Peutz-Jeghers syndrome
    Medical condition: Advanced malignancy of any tumor type, not suitable for surgery at the time of study enter in patients with known Peutz-Jeghers disease (with LKB1 mutation).
    Disease: Version SOC Term Classification Code Term Level
    12.1 10034764 Peutz-Jeghers syndrome PT
    12.1 10029111 Neoplasms unspecified malignancy and site unspecified NEC HLT
    12.1 10034764 Peutz-Jeghers syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002786-39 Sponsor Protocol Number: SAREFU Start Date*: 2007-09-14
    Sponsor Name:AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" (A.O. DI RILIEVO NAZIONALE)
    Full Title: A PROSPECTIVE TRIAL , MONOCENTRIC, RANDOMIZED, TO EVALUATE THE RENAL'S FUNCTION IN SUBJECTS WITH CARDIAC TRANSPLANTED
    Medical condition: CARDIAC-TRASPLATED
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048870 Prophylaxis against transplant rejection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 19:45:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA